Corbus Pharmaceuticals Holdings Inc (CRBP) Expected to Announce Earnings of $0.02 Per Share

Wall Street analysts expect Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) to report earnings per share (EPS) of $0.02 for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Corbus Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.31) and the highest is $0.17. Corbus Pharmaceuticals reported earnings of ($0.21) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 109.5%. The business is scheduled to report its next earnings report on Thursday, May 9th.

On average, analysts expect that Corbus Pharmaceuticals will report full-year earnings of ($0.88) per share for the current financial year, with EPS estimates ranging from ($1.22) to ($0.53). For the next fiscal year, analysts expect that the business will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.91) to ($1.02). Zacks’ EPS averages are an average based on a survey of analysts that cover Corbus Pharmaceuticals.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.07). Corbus Pharmaceuticals had a negative return on equity of 116.34% and a negative net margin of 1,154.52%. The firm had revenue of $1.93 million during the quarter, compared to the consensus estimate of $1.99 million.

CRBP has been the topic of several analyst reports. HC Wainwright initiated coverage on Corbus Pharmaceuticals in a research note on Wednesday, December 26th. They set a “buy” rating and a $24.00 price objective on the stock. BidaskClub raised Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, December 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $38.00 price objective (up from $36.00) on shares of Corbus Pharmaceuticals in a research note on Friday, January 11th. ValuEngine cut Corbus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 24th. Finally, Zacks Investment Research cut Corbus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $23.59.

In other Corbus Pharmaceuticals news, insider Barbara White bought 4,638 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was acquired at an average price of $6.47 per share, for a total transaction of $30,007.86. Following the completion of the transaction, the insider now directly owns 184,159 shares of the company’s stock, valued at $1,191,508.73. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have acquired 8,668 shares of company stock worth $56,923 over the last three months. 12.60% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its position in shares of Corbus Pharmaceuticals by 6.7% during the fourth quarter. Bank of America Corp DE now owns 37,304 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 2,335 shares during the period. Barclays PLC boosted its position in shares of Corbus Pharmaceuticals by 5,967.8% during the fourth quarter. Barclays PLC now owns 9,041 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 8,892 shares during the period. Vanguard Group Inc. boosted its position in shares of Corbus Pharmaceuticals by 0.5% during the third quarter. Vanguard Group Inc. now owns 2,390,014 shares of the biopharmaceutical company’s stock valued at $18,045,000 after buying an additional 11,609 shares during the period. Vanguard Group Inc boosted its position in shares of Corbus Pharmaceuticals by 0.5% during the third quarter. Vanguard Group Inc now owns 2,390,014 shares of the biopharmaceutical company’s stock valued at $18,045,000 after buying an additional 11,609 shares during the period. Finally, Cambridge Investment Research Advisors Inc. boosted its position in shares of Corbus Pharmaceuticals by 32.5% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 47,534 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 11,650 shares during the period. Institutional investors and hedge funds own 40.21% of the company’s stock.

NASDAQ CRBP traded down $0.27 during trading hours on Friday, hitting $6.94. 28,750 shares of the company were exchanged, compared to its average volume of 1,510,234. Corbus Pharmaceuticals has a 52 week low of $4.50 and a 52 week high of $9.11. The stock has a market capitalization of $452.51 million, a P/E ratio of -7.08 and a beta of 2.16.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases.

Further Reading: Preferred Stock

Get a free copy of the Zacks research report on Corbus Pharmaceuticals (CRBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.